Augmenting anti-tumor efficacy of adoptive immunotherapy with marrow infiltrating lymphocytes

Published: June 3, 2009
Abstract Views: 131
PDF: 180
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Despite the ability to generate tumor-specific immunity in both murine and human models, the efficacy of immune-based therapeutic interventions has met with limited success. Effective immunotherapy requires: the precursor frequency of antigen specific T cells be present in sufficient numbers; T cell trafficking to the tumor site; and recognition and killing of their target upon antigen encounter. We have taken a step-wise approach in an effort to address these issues. We utilized a whole tumor cell approach in conjunction with a GM-CSF – producing bystander cell in an effort to prime an immune response towards a broad range of tumor antigens and simplify vaccine production.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Borrello, I. (2009). Augmenting anti-tumor efficacy of adoptive immunotherapy with marrow infiltrating lymphocytes. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.287